EP1547585A1 — Therapeutic agent for rheumatism containing benzamide derivative as active ingredient
Assigned to Santen Pharmaceutical Co Ltd · Expires 2005-06-29 · 21y expired
What this patent protects
An object of the present invention is to provide a therapeutic agent for rheumatic diseases comprising a benzamide derivative as an active ingredient. The benzamide derivative according to the present invention is a compound represented by the following general formula Ä1Ü or a s…
USPTO Abstract
An object of the present invention is to provide a therapeutic agent for rheumatic diseases comprising a benzamide derivative as an active ingredient. The benzamide derivative according to the present invention is a compound represented by the following general formula Ä1Ü or a salt thereof as an active ingredient. In the formula, R<1>, R<2> and R<3>, the same or different, are hydrogen, halogen, hydroxyl, lower alkyl, lower alkoxy, aryl, aryl-lower alkyl, aryloxy, amino, amino-lower alkyl, lower alkylamino or carboxyl, X is aryl or a heterocycle, Y is a direct bond or lower alkylene wherein the lower alkylene can contain oxygen atom(s) in the group, and Z is a direct bond or lower alkylene. <CHEM>
Drugs covered by this patent
- Ojemda (TOVORAFENIB) · Day One Biopharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.